Schizophrenia Research
Volume 100, Issue 1 , Pages 70-85 , March 2008

Impact of atypical antipsychotic therapy on leptin, ghrelin, and adiponectin

  • Hua Jin

      Affiliations

    • Department of Psychiatry, University of California at San Diego, USA
    • Psychiatric Service, San Diego VA Healthcare System, USA
    • Corresponding Author InformationCorresponding author. Department of Psychiatry, University of California at San Diego, USA. Tel.: +1 858 642 3904.
    • ,
  • Jonathan M. Meyer

      Affiliations

    • Department of Psychiatry, University of California at San Diego, USA
    • Psychiatric Service, San Diego VA Healthcare System, USA
    • ,
  • Sunder Mudaliar

      Affiliations

    • Department of Medicine, endocrinology division, UCSD and San Diego VA Healthcare System, 3350 La Jolla Village Drive, La Jolla, CA 92161, USA
    • ,
  • Dilip V. Jeste

      Affiliations

    • Department of Psychiatry, University of California at San Diego, USA
    • Psychiatric Service, San Diego VA Healthcare System, USA

Received 4 April 2007 ,Revised 15 November 2007 ,Accepted 19 November 2007.

References 

  1. Allison DB, Casey DE. Antipsychotic-induced weight gain: a review of the literature. Journal of Clinical Psychiatry. 2001;62:22–31
  2. Amamoto T, Kumai T, Nakaya S, Matsumoto N, Tsuzuki Y, Kobayashi S. The elucidation of the mechanism of weight gain and glucose tolerance abnormalities induced by chlorpromazine. Journal of Pharmacology Science. 2006;102:213–219
  3. American Diabetes Association, America Psychiatric Association, American Association of Clinical Endocrinologists, North American Association for the Study of Obesity . Consensus development conference on antipsychotic drugs and obesity and diabetes. Journal of Clinical Psychiatry. 2004;65:267–272
  4. Arita Y, Kihara S, Ouchi N, Takahashi M, Maeda K, Miyagawa J, et al. Paradoxical decrease of an adipose-specific protein, adiponectin, in obesity. Biochemical and Biophysical Research Communications. 1999;257:79–83
  5. Arranz B, Rosel P, Ramirez N, Duenas R, Fernandez P, Sanchez JM, et al. Insulin resistance and increased leptin concentrations in noncompliant schizophrenia patients but not in antipsychotic-naive first-episode schizophrenia patients. Journal of Clinical Psychiatry. 2004;65:1335–1342
  6. Atmaca M, Kuloglu M, Tezcan E, Gecici O, Ustundag B. Weight gain, serum leptin and triglyceride levels in patients with schizophrenia on antipsychotic treatment with quetiapine, olanzapine and haloperidol. Schizophrenia Research. 2003;60:99–100
  7. Atmaca M, Kuloglu M, Tezcan E, Ustundag B. Nizatidine treatment and its relationship with leptin levels in patients with olanzapine-induced weight gain. Human Psychopharmacology. 2003;18:457–461
  8. Atmaca M, Kuloglu M, Tezcan E, Ustundag B. Serum leptin and triglyceride levels in patients on treatment with atypical antipsychotics. Journal of Clinical Psychiatry. 2003;64:598–604
  9. Atmaca M, Kuloglu M, Tezcan E, Ustundag B, Kilic N. Nizatidine for the treatment of patients with quetiapine-induced weight gain. Human Psychopharmacology. 2004;19:37–40
  10. Atmaca M, Tezcan E, Ustundag B. Plasma nitric oxide and leptin values in patients with olanzapine-induced weight gain. Journal of Psychiatric Research. 2007;41:74–79
  11. Baptista T, Beaulieu S. Are leptin and cytokines involved in body weight gain during treatment with antipsychotic drugs?. Canadian Journal of Psychiatry. 2002;47:742–749
  12. Baptista T, Lacruz A, de Mendoza S, Mendoza Guillen JM, Silvera R, Angeles F, et al. Body weight gain after administration of antipsychotic drugs: correlation with leptin, insulin and reproductive hormones. [see comment] Pharmacopsychiatry. 2000;33:81–88
  13. Baptista T, Lacruz A, Angeles F, Silvera R, de Mendoza S, Mendoza MT, et al. Endocrine and metabolic abnormalities involved in obesity associated with typical antipsychotic drug administration. Pharmacopsychiatry. 2001;34:223–231
  14. Basile VS, Masellis M, McIntyre RS, Meltzer HY, Lieberman JA, Kennedy JL. Genetic dissection of atypical antipsychotic-induced weight gain: novel preliminary data on the pharmacogenetic puzzle. Journal of Clinical Psychiatry. 2001;62:45–66
  15. Batterham RL, Bloom SR. The gut hormone peptide YY regulates appetite. Annals of the New York Academy of Sciences. 2003;994:162–168
  16. Birkas Kovats D, Palik E, Faludi G, Cseh K. Possible connection between ghrelin, resistin and TNF-alpha levels and the metabolic syndrome caused by atypical antipsychotics. Neuropsychopharmacologia Hungarica. 2005;7:132–139
  17. Bromel T, Blum WF, Ziegler A, Schulz E, Bender M, Fleischhaker C, et al. Serum leptin levels increase rapidly after initiation of clozapine therapy. Molecular Psychiatry. 1998;3:76–80
  18. Chiu C-C, Chen K-P, Liu H-C, Lu M-L. The early effect of olanzapine and risperidone on insulin secretion in atypical-naive schizophrenic patients. Journal of Clinical Psychopharmacology. 2006;26:504–507
  19. Cooper GD, Pickavance LC, Wilding JPH, Halford JCG, Goudie AJ. A parametric analysis of olanzapine-induced weight gain in female rats. Psychopharmacology. 2005;181:80–89
  20. Correll CU, Malhotra AK. Pharmacogenetics of antipsychotic-induced weight gain. Psychopharmacology (Berl). 2004;174:477–489
  21. Ebenbichler C, Laimer M, Kranebitter M, Lechleitner M, Patsch JR, Baumgartner S, et al. The soluble leptin receptor in olanzapine-induced weight gain: results from a prospective study. Schizophrenia Research. 2005;75:143–146
  22. Eder U, Mangweth B, Ebenbichler C, Weiss E, Hofer A, Hummer M, et al. Association of olanzapine-induced weight gain with an increase in body fat. American Journal of Psychiatry. 2001;158:1719–1722
  23. Fitzgerald PB, Scaffidi A, Morris MJ, de Castella AR, Kulkarni J. The relationship of changes in leptin, neuropeptide Y and reproductive hormones to antipsychotic induced weight gain. Human Psychopharmacology. 2003;18:551–557
  24. Franks PW, Brage S, Luan JA, Ekelund U, Rahman M, Farooqi IS, et al. Leptin predicts a worsening of the features of the metabolic syndrome independently of obesity. Obesity Research. 2005;13:1476–1484
  25. Friedman, J.M., 2002. The function of leptin in nutrition, weight, and physiology. Nutrition Reviews 60, S1-14; discussion S68–S84.
  26. Gale SM, Castracane VD, Mantzoros CS. Energy homeostasis, obesity and eating disorders: recent advances in endocrinology. Journal of Nutrition. 2004;134:295–298
  27. Gergerlioglu HS, Savas HA, Celik A, Savas E, Yumru M, Tarakcioglu M, et al. Atypical antipsychotic usage-related higher serum leptin levels and disabled lipid profiles in euthymic bipolar patients. Neuropsychobiology. 2006;53:108–112
  28. Graham KA, Gu H, Lieberman JA, Harp JB, Perkins DO. Double-blind, placebo-controlled investigation of amantadine for weight loss in subjects who gained weight with olanzapine. American Journal of Psychiatry. 2005;162:1744–1746
  29. Graham KA, Perkins DO, Edwards LJ, Barrier RC, Lieberman JA, Harp JB. Effect of olanzapine on body composition and energy expenditure in adults with first-episode psychosis. [see comment] American Journal of Psychiatry. 2005;162:118–123
  30. Hagg S, Soderberg S, Ahren B, Olsson T, Mjorndal T. Leptin concentrations are increased in subjects treated with clozapine or conventional antipsychotics. Journal of Clinical Psychiatry. 2001;62:843–848
  31. Halaas JL, Gajiwala KS, Maffei M, et al. Weight reducing effects of the plasma protein encoded by the obese gene. Science. 1995;269:543–546
  32. Hauner H, Rohrig K, Hebebrand J, Skurk T. No evidence for a direct effect of clozapine on fat-cell formation and production of leptin and other fat-cell-derived factors. Molecular Psychiatry. 2003;8:258–259
  33. Haupt DW, Luber A, Maeda J, Melson AK, Schweiger JA, Newcomer JW. Plasma leptin and adiposity during antipsychotic treatment of schizophrenia. [see comment] Neuropsychopharmacology. 2005;30:184–191
  34. Herran A, Garcia-Unzueta MT, Amado JA, de La Maza MT, Alvarez C, Vazquez-Barquero JL. Effects of long-term treatment with antipsychotics on serum leptin levels. [see comment] British Journal of Psychiatry. 2001;179:59–62
  35. Himmerich H, Fulda S, Kunzel HE, Pfennig A, Dzaja A, Cummings DE, et al. Ghrelin plasma levels during psychopharmacological treatment. Neuropsychobiology. 2005;52:11–16
  36. Hinze-Selch D, Deuschle M, Weber B, Heuser I, Pollmacher T. Effect of coadministration of clozapine and fluvoxamine versus clozapine monotherapy on blood cell counts, plasma levels of cytokines and body weight. Psychopharmacology. 2000;149:163–169
  37. Horvath TL, Diano S, Sotonyi P, Heiman M, Tschop M. Minireview: ghrelin and the regulation of energy balance—a hypothalamic perspective. Endocrinology. 2001;142:163–169
  38. Horvath TL, Castaneda T, Tang-Christensen M, Pagotto U, Tschop MH. Ghrelin as a potential anti-obesity target. Current Pharmaceutical Design. 2003;9:1383–1395
  39. Hosojima H, Togo T, Odawara T, Hasegawa K, Miura S, Kato Y, et al. Early effects of olanzapine on serum levels of ghrelin, adiponectin and leptin in patients with schizophrenia. Journal of Psychopharmacology. 2006;20:75–79
  40. Houseknecht KL, Robertson AS, Zavadoski W, Gibbs EM, Johnson DE, Rollema H. Acute effects of atypical antipsychotics on whole body insulin resistance in rats: implications for adverse metabolic effects. Neuropsychopharmacology. 2007;32:289–297
  41. Jin H, Meyer JM, Jeste DV. Phenomenology of and risk factors for new-onset diabetes mellitus and diabetic ketoacidosis associated with atypical antipsychotics: an analysis of 45 published cases. Annals of Clinical Psychiatry. 2002;14:59–64
  42. Jin H, Meyer JM, Jeste DV. Atypical antipsychotics and glucose dysregulation: a systematic review. Schizophrenia Research. 2004;71:195–212
  43. Kim SF, Huang AS, Snowman AM, Teuscher C, Snyder SH. Antipsychotic drug-induced weight gain mediated by histamine H1 receptor-linked activation of hypothalamic AMP-kinase. Proceedings of the National Academy of Sciences of the United States of America. 2007;104:3456–3459
  44. Kivircik BB, Alptekin K, Caliskan S, Comlekci A, Oruk G, Tumuklu M, et al. Effect of clozapine on serum leptin, insulin levels, and body weight and composition in patients with schizophrenia. Progress in Neuro-Psychopharmacology & Biological Psychiatry. 2003;27:795–799
  45. Kojima M, Hosoda H, Date Y, Nakazato M, Matsuo H, Kangawa K. Ghrelin is a growth-hormone-releasing acylated peptide from stomach. Nature. 1999;402:656–660
  46. Koller EA, Doraiswamy PM. Olanzapine-associated diabetes mellitus. Pharmacotherapy. 2002;22:841–852
  47. Koller E, Schneider B, Bennett K, Dubitsky G. Clozapine-associated diabetes. American Journal of Medicine. 2001;111:716–723
  48. Koller EA, Cross JT, Doraiswamy PM, Schneider BS. Risperidone-associated diabetes mellitus: a pharmacovigilance study. Pharmacotherapy. 2003;23:735–744
  49. Koller E, Weber J, Doraiswamy PM, Schneider BS. A survey of reports of quetiapine-associated hyperglycemia and diabetes mellitus. Journal of Clinical Psychiatry. 2004;65:857–863
  50. Korner J, Leibel RL. To eat or not to eat — how the gut talks to the brain. New England Journal of Medicine. 2003;349:926–928
  51. Kraus T, Haack M, Schuld A, Hinze-Selch D, Kuhn M, Uhr M, et al. Body weight and leptin plasma levels during treatment with antipsychotic drugs. American Journal of Psychiatry. 1999;156:312–314
  52. Kroeze WK, Hufeisen SJ, Popadak BA, Renock SM, Steinberg S, Ernsberger P, et al. H1-histamine receptor affinity predicts short-term weight gain for typical and atypical antipsychotic drugs. Neuropsychopharmacology. 2003;28:519–526
  53. Lieberman JA, Stroup TS, McEvoy JP, Swartz MS, Rosenheck RA, Perkins DO, et al. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. New England Journal of Medicine. 2005;353:1209–1223
  54. Lucidi P, Murdolo G, Di Loreto C, Parlanti N, De Cicco A, Ranchelli A, et al. Meal intake similarly reduces circulating concentrations of octanoyl and total ghrelin in humans. Journal of Endocrinological Investigation. 2004;27:RC12–RC15
  55. Maeda K, Okubo K, Shimomura I, Funahashi T, Matsuzawa Y, Matsubara K. cDNA cloning and expression of a novel adipose specific collagen-like factor, apM1 (AdiPose most abundant gene transcript 1). Biochemical and Biophysical Research Communications. 1996;221:286–289
  56. Mantel-Teeuwisse AK, Kloosterman JM, Maitland-van der Zee AH, Klungel OH, Porsius AJ, de Boer A. Drug-induced lipid changes: a review of the unintended effects of some commonly used drugs on serum lipid levels. Drug Safety. 2001;24:443–456
  57. Martin A, Scahill L, Anderson GM, Aman M, Arnold LE, McCracken J, et al. Weight and leptin changes among risperidone-treated youths with autism: 6-month prospective data. American Journal of Psychiatry. 2004;161:1125–1127
  58. McEvoy JP, Meyer JM, Nasrallah HA, Goff DC, Davis SM, Sullivan L, et al. Prevalence of the metabolic syndrome in patients with schizophrenia: baseline results from the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) Schizophrenia Trial and comparison with national estimates from NHANES III. Schizophrenia Research. 2005;80:19–32
  59. McIntyre RS, Mancini DA, Basile VS, Srinivasan J, Kennedy SH. Antipsychotic-induced weight gain: bipolar disorder and leptin. Journal of Clinical Psychopharmacology. 2003;23:323–327
  60. Melkersson KI, Hulting AL. Insulin and leptin levels in patients with schizophrenia or related psychoses—a comparison between different antipsychotic agents. Psychopharmacology. 2001;154:205–212
  61. Melkersson KI, Dahl ML. Relationship between levels of insulin or triglycerides and serum concentrations of the atypical antipsychotics clozapine and olanzapine in patients on treatment with therapeutic doses. Psychopharmacology. 2003;170:157–166
  62. Melkersson KI, Hulting AL, Brismar KE. Elevated levels of insulin, leptin, and blood lipids in olanzapine-treated patients with schizophrenia or related psychoses. [see comment] Journal of Clinical Psychiatry. 2000;61:742–749
  63. Meyer JM. A retrospective comparison of weight, lipid, and glucose changes between risperidone- and olanzapine-treated inpatients: metabolic outcomes after 1 year. Journal of Clinical Psychiatry. 2002;63:425–433
  64. Meyer JM, Koro CE. The effects of antipsychotic therapy on serum lipids: a comprehensive review. Schizophrenia Research. 2004;70:1–17
  65. Monteleone P, Fabrazzo M, Tortorella A, La Pia S, Maj M. Pronounced early increase in circulating leptin predicts a lower weight gain during clozapine treatment. Journal of Clinical Psychopharmacology. 2002;22:424–426
  66. Murashita M, Kusumi I, Inoue T, Takahashi Y, Hosoda H, Kangawa K, et al. Olanzapine increases plasma ghrelin level in patients with schizophrenia. Psychoneuroendocrinology. 2005;30:106–110
  67. Murashita M, Inoue T, Kusumi I, Nakagawa S, Itoh K, Tanaka T, et al. Glucose and lipid metabolism of long-term risperidone monotherapy in patients with schizophrenia. Psychiatry and Clinical Neurosciences. 2007;61:54–58
  68. Nakano Y, Tobe T, Choi-Miura NH, Mazda T, Tomita M. Isolation and characterization of GBP28, a novel gelatin-binding protein purified from human plasma. Journal of Biochemistry(Tokyo). 1996;120:803–812
  69. Newcomer JW. Second-generation (atypical) antipsychotics and metabolic effects: a comprehensive literature review. CNS Drugs. 2005;19:1–95
  70. Pajvani UB, Du X, Combs TP, Berg AH, Rajala MW, Schulthess T, et al. Structure–function studies of the adipocyte-secreted hormone Acrp30/adiponectin. Implications for metabolic regulation and bioactivity. Journal of Biological Chemistry. 2003;14:9073–9085
  71. Palik E, Birkas KD, Faludi G, Karadi I, Cseh K. Correlation of serum ghrelin levels with body mass index and carbohydrate metabolism in patients treated with atypical antipsychotics. Diabetes Research and Clinical Practice. 2005;68(Suppl1):S60–S64
  72. Richards AA, Hickman IJ, Wang AYH, Jones AL, Newell F, Mowry BJ, et al. Olanzapine treatment is associated with reduced high molecular weight adiponectin in serum: a potential mechanism for olanzapine-induced insulin resistance in patients with schizophrenia. Journal of Clinical Psychopharmacology. 2006;26:232–237
  73. Ruano G, Goethe JW, Caley C, Woolley S, Holford TR, Kocherla M, et al. Physiogenomic comparison of weight profiles of olanzapine-and risperidone-treated patients. Molecular Psychiatry. 2007;12(5):474–482
  74. Rustembegovic A, Sofic E, Wichart I. Serum prolactin, leptin, lipids and lipoproteins levels during antipsychotics treatment in Parkinson's disease and related psychosis. Medicinski Arhiv. 2006;60:211–212
  75. Sathyaprakash R, Henry RR. Hyperglycemia with antipsychotic treatment. Current Diabetes Reports. 2004;4:41–45
  76. Smith RC, Lindenmayer J-P, Bark N, Warner-Cohen J, Vaidhyanathaswamy S, Khandat A. Clozapine, risperidone, olanzapine, and conventional antipsychotic drug effects on glucose, lipids, and leptin in schizophrenic patients. [see comment] International Journal of Neuropsychopharmacology. 2005;8:183–194
  77. Sondhi S, Castellano JM, Chong VZ, Rogoza RM, Skoblenick KJ, Dyck BA, et al. cDNA array reveals increased expression of glucose-dependent insulinotropic polypeptide following chronic clozapine treatment: role in atypical antipsychotic drug-induced adverse metabolic effects. Pharmacogenomics Journal. 2006;6:131–140
  78. Sporn AL, Bobb AJ, Gogtay N, Stevens H, Greenstein DK, Clasen LS, et al. Hormonal correlates of clozapine-induced weight gain in psychotic children: an exploratory study. Journal of the American Academy of Child and Adolescent Psychiatry. 2005;44:925–933
  79. Tatemoto K, Mutt V. Isolation of two novel candidate hormones using a chemical method for finding naturally occurring polypeptides. Nature. 1980;285:417–418
  80. Templeman LA, Reynolds GP, Arranz B, San L. Polymorphisms of the 5-HT2C receptor and leptin genes are associated with antipsychotic drug-induced weight gain in Caucasian subjects with a first-episode psychosis. [see comment] Pharmacogenetics & Genomics. 2005;15:195–200
  81. Theisen FM, Gebhardt S, Bromel T, Otto B, Heldwein W, Heinzel-Gutenbrunner M, et al. A prospective study of serum ghrelin levels in patients treated with clozapine. Journal of Neural Transmission. 2005;112:1411–1416
  82. Togo T, Hasegawa K, Miura S, Hosojima H, Kojima K, Shoji M, et al. Serum ghrelin concentrations in patients receiving olanzapine or risperidone. Psychopharmacology. 2004;172:230–232
  83. Togo T, Kojima K, Shoji M, Kase A, Uchikado H, Katsuse O, et al. Serum adiponectin concentrations during treatment with olanzapine or risperidone: a pilot study. International Clinical Psychopharmacology. 2004;19:37–40
  84. Tschop M, Smiley DL, Heiman ML. Ghrelin induces adiposity in rodents. Nature. 2000;407:908–913
  85. Waki H, Yamauchi T, Kamon J, Ito Y, Uchida S, Kita S, et al. Impaired multimerization of human adiponectin mutants associated with diabetes. Molecular structure and multimer formation of adiponectin. Journal of Biological Chemistry. 2003;278:40352–40363
  86. Wallace AM, McMahon AD, Packard CJ, Kelly A, Shepherd J, Gaw A, et al. Plasma leptin and the risk of cardiovascular disease in the west of Scotland coronary prevention study (WOSCOPS). [see comment] Circulation. 2001;104:3052–3056
  87. Wang CJ, Zhang ZJ, Sun J, Zhang XB, Mou XD, Zhang XR, et al. Serum free fatty acids and glucose metabolism, insulin resistance in schizophrenia with chronic antipsychotics. Biological Psychiatry. 2006;60:1309–1313
  88. Weyer C, Funahashi T, Tanaka S, Hotta K, Matsuzawa Y, Pratley RE, et al. Hypoadiponectinemia in obesity and type 2 diabetes: close association with insulin resistance and hyperinsulinemia. Journal of Clinical Endocrinology and Metabolism. 2001;86:1930–1935
  89. Wirshing DA, Boyd JA, Meng LR, Ballon JS, Marder SR, Wirshing WC. The effects of novel antipsychotics on glucose and lipid levels. Journal of Clinical Psychiatry. 2002;63:856–865
  90. Zhang Y, Proenca R, Maffei M, Barone M, Leopold L, Friedman JM. Positional cloning of the mouse obese gene and its human homologue. [see comment] [erratum appears in Nature 1995 Mar 30;374(6521):479] Nature. 1994;372:425–432
  91. Zhang ZJ, Yao ZJ, Mou XD, Chen JF, Zhu RX, Liu W, et al. Association of −2548G/A functional polymorphism in the promoter region of leptin gene with antipsychotic agent-induced weight gain. Chung-Hua i Hsueh Tsa Chih [Chinese Medical Journal]. 2003;83:2119–2123
  92. Zhang ZJ, Yao ZJ, Liu W, Fang Q, Reynolds GP. Effects of antipsychotics on fat deposition and changes in leptin and insulin levels. Magnetic resonance imaging study of previously untreated people with schizophrenia. Br J Psychiatry. 2004;18(4):58–62
  93. Zhang JV, Ren PG, Avsian-Kretchmer O, Luo CW, Rauch R, Klein C, et al. Obestatin, a peptide encoded by the ghrelin gene, opposes ghrelin's effects on food intake. Science. 2005;310:996–999

☆ This study is supported, in part, by the National Institute of Mental Health grants (MH071536) and by the department of Veterans Affairs.

PII: S0920-9964(07)00538-5

doi: 10.1016/j.schres.2007.11.026

Schizophrenia Research
Volume 100, Issue 1 , Pages 70-85 , March 2008

Article Tools